Clinical Trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Study acronym: TRIPLE-SWITCH
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Protocol Amendment History 3 changes
notable Trial sites expanded: 368 -> 395 locations 2026-07-15
notable Trial sites expanded: 340 -> 368 locations 2026-06-10
notable Trial sites expanded: 310 -> 340 locations 2026-04-15
Trial Details
NCT Number NCT06592924
Lead Sponsor Canadian Cancer Trials Group
Collaborators: ECOG-ACRIN Cancer Research Group, NRG Oncology, Alliance for Clinical Trials in Oncology, SWOG Cancer Research Network
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 830 participants
Start Date 2025-05-28
Primary Completion 2031-03-14 (estimated)
Study Completion 2031-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-14